Myelomatous pleural effusion involvement in 23 patients with multiple myeloma: A single‐center clinical analysis

Thoracic Cancer

Yuping Zhong¹  Jiajia Zhang¹ 

[1] Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

关键词: Bortezomib;    multiple myeloma;    myelomatous pleural effusion;    prognosis;   

DOI  :  10.1111/1759-7714.12220

来源: Wiley

【 摘 要 】

Abstract

We investigated the treatment and prognosis of pleural effusion (PE) in multiple myeloma (MM) patients. From June 2005 to December 2013, 296 MM patients participated in this study. There were 23 PE patients, including 11 men and 12 women, with a median age of 56.8 years (range 37–68 years). A diagnosis of PE was based on physical examination, chest X-ray or computed tomography, and pleural fluid analysis. All patients demonstrated myeloma cells in the pleural fluid, and six patients were positive for PE M protein. PE patients received bortezomib combined with other drugs. Only one patient demonstrated a complete response; 10 patients showed partial responses, and 12 patients developed progressive disease and died. MM linked with myelomatous PE is associated with a poor prognosis. Myelomatous PE is likely a late manifestation of the natural history of MM or an expression of the aggressive behavior of the disease.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Thoracic Cancer published by Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.